Bjørn-Eivind Kirsebom

Oct 25, 2024 | journals.sagepub.com | Julia Gundersen |Fernando Gonzalez-Ortiz |Thomas K. Karikari |Bjørn-Eivind Kirsebom

Introduction Acute ischemic stroke (AIS), a leading cause of mortality and long-term disability, poses an enormous global burden.1,2 Thrombolysis and thrombectomy are highly effective but time-sensitive treatments that improve long-term outcome after AIS.3 Approximately 25% of patients presenting with AIS have a non-ischemic neurological or non-neurological condition, such as peripheral vestibular dysfunction (23.2%), seizures (13.0%) functional disorders (9.7%) and migraine (7.8%).4...